Latest Industry Insights

Three-dimensional interactions across the genome can impact gene expression, and understanding these interactions could offer new insights into oncogenic mechanisms.

To learn more about the world's first Microhub – Mica – and some of the areas it could impact the most, Technology Networks spoke to James O’Brien, vice president life sciences at Leica Microsystems.

Technology Networks recently spoke with Jakob Dupont, head of global research & development at Atara Bio, to learn more about the company’s novel allogeneic EBV T-cell platform and discover how it’s enabling a differentiated approach to allogeneic cell therapy.

In honor of International Day of Women and Girls in Science 2022, Technology Networks interviewed three women who have built successful careers within the scientific industry, to learn about their career paths and the reasons they chose to work in industry.

Next-generation sequencing (NGS) has undoubtedly revolutionized the genomics field and thanks to technological advances in recent years, laboratories around the globe are now applying NGS to a wide variety of applications. However, library sample preparation remains a key bottleneck and researchers are now looking to adopt automation solutions to alleviate this pain point. Technology Networks recently spoke with Paul Lomax, product manager at SPT Labtech to learn more about firefly^®, the company’s new liquid handling platform for NGS library preparation.

Laboratories often consume three to 10 times more energy than typical non-laboratory areas of universities. We spoke to Dr Susan Simon of the Medical Research Council to learn more about their commitment to sustainability and transformation to net zero by 2040.

In this interview, Greg Gosch shares insights into the science of multiplexing, discusses how ChromaCode is redefining molecular diagnostics and explores how HDPCR is shaping the future of what’s possible in COVID-19, related respiratory and other disease testing.

Single-cell technologies are transforming our knowledge of human health and disease. In this article, Gary Kruppa outlines the latest advances in single-cell proteomics.

In this interview, Murat Kalayoglu, president and CEO of Cartesian Therapeutics discusses the company’s efforts to develop RNA-modified cell therapies that expand past oncology.

To find out more about how AI can improve melanoma diagnosis, Technology Networks spoke to Dr. Kiran Motaparthi, director of dermatopathology and clinical associate professor of dermatology at the University of Florida and Julianna Ianni, PhD, vice president of AI R&D, Proscia.